Letters to the Editor
Vol. 94 No. 4 (2022)
https://doi.org/10.4081/aiua.2022.4.521
Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 30 October 2022
Published: 28 December 2022
Published: 28 December 2022
1860
Views
4661
Downloads
To the Editor,
Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in elderly males. The current guidelines recommend the use of a 5-alpha reductase inhibitor (5ARI) to treat males with moderate-to-severe LUTS and an enlarged prostate. Combination therapy with an alpha blocker and a 5ARI has proven effective at ameliorating LUTS and reducing the total prostate volume (TPV) and the risk of the disease progression.
Downloads
Download data is not yet available.
How to Cite
Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy. (2022). Archivio Italiano Di Urologia E Andrologia, 94(4), 521-524. https://doi.org/10.4081/aiua.2022.4.521
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.